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Increasing the Complexity Minireview
of Coactivation in
Nuclear Receptor Signaling
receptor LBDs converged on a family of related proteins
that are collectively termed the p160 coactivators. They
are represented by SRC-1/NCoA-1, TIF2/GRIP1/NCoA-2,
and pCIP/ACTR/AIB1 (see Xu et al., 1999 and references
therein). LBDs were used as baits since an essential
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ligand-dependent transactivation function maps to the
C terminus of this domain (AF2; Figure 1). A second,Nuclear receptors lead somewhat of a double life. In
ligand-independent activation function (AF1) residesmany respects, these proteins are indistinguishable
within the N terminus of many but not all nuclear recep-from other eukaryotic factors that regulate transcription.
tors. Besides sequence homology, p160 proteins shareNuclear receptors bind selectively to DNA, primarily as
an ability to stimulate ligand-dependent transactivationdimers through two characteristic zinc finger modules
by a rather large number of nuclear receptors in transient
and a dimerization region that directs self-interaction or
overexpression experiments. A distinctive structural fea-
hetero-partnering. Moreover, they possess identifiable
ture of the p160 coactivators is the presence of multiple
activation functions (AFs) that confer transactivation po-
LXXLL signature motifs (also called LXDs, NR boxes, or
tential to heterologous DNA-binding domains. However, NIDs), which comprise determinants for direct interac-
an important feature of nuclear receptors that distin- tions with the nuclear receptor LBD.
guishes them from other transcription factors is that Although the amino acid context surrounding the
these proteins possess a hair-trigger switch, which is LXXLL motif appears to influence selectivity of interac-
conferred by their ligand-binding domain (LBD). It is here tion, it is unclear at this point what, if anything, influences
that the receptors have evolved their uncanny ability to the specificity of nuclear receptor/p160 binding. Several
stifle intrinsic transactivation potentials when not bound recent LBD crystal structures have established that
by their cognate ligands and to immediately induce them upon ligand binding, the a helix containing the AF2 core
when a given ligand makes a stereospecific, high-affinity (helix 12) undergoes a major reorientation in the context
interaction with a pocket in the LBD waiting to accomo- of the overall LBD structure, forming part of a ªcharged
date it. clampº that accommodates p160 coactivators within a
The ligands for nuclear receptors include steroids, hydrophobic cleft of the LBD; this occurs through direct
retinoids, vitamin D, thyroid hormone, prostanoids, and contacts with the LXXLL motif (reviewed in Xu et al.,
farnesoids. Their combined effects are vast, influencing 1999). Remarkably, estrogen antagonists such as ta-
virtually every fundamental biological process, from de- moxifen and raloxifene appear to alter the position of
velopment and homeostasis, to proliferation and differ- the AF2 core such that helix 12 itself occupies the hy-
entiation. As more ligands have been uncovered for or- drophobic cleft in the LBD, thereby precluding coactiva-
phan receptors, it is becoming increasingly apparent tor binding (Brzozowski et al., 1997; Shiau et al., 1998).
that nonendocrine pathways, including those involving In fact, several experiments preceding these crystal
structure analyses indicated that a key mechanistic ef-protein kinases and metabolic products, are also re-
fect of hormonal antagonists is to inhibit p160 interactionsponsible for signaling. Because this family of receptors
with the LBD, supporting the biological relevance ofare intracellular, they are direct mediators of the action
coactivators in nuclear receptor function.of their cognate hormone. Although some steroid recep-
Insight into a potential mechanism of p160 coactiva-tors are compartmentalized initially to the cytoplasm as
tion came with the finding that SRC-1 is capable ofcomplexes with heat shock proteins acting as chaper-
interacting with the C terminus of CBP/p300 and to-ones and subsequently translocate to the nucleus as
gether they can coactivate synergistically (Yao et al.,a consequence of ligand binding, most receptors are
1996). In addition, CBP/p300 itself interacts directly withprelocalized to the nucleus. How then do the ligands
nuclear receptors in a ligand-dependent manner, againexert their inducing effects on nuclear receptor activity
through the AF2 domain (Chakravarti et al., 1996; Kameiif they already reside in the nucleus (presumably DNA-
et al., 1996). CBP/p300 and p160 coactivators both pos-bound), and how do some receptors become activated
sess intrinsic histone acetyl transferase (HAT) activityby kinase cascades independently of their cognate li-
and therefore may be acting in concert to remodel chro-gands? The answer appears to be reflected in another
matin. Moreover, p/CAF, the mammalian homolog of the
aspect of the double life of nuclear receptors: an initial
association with transcriptional corepressors and sub-
sequent ability to recruit coactivators in response to
ligands and other signals. A rapidly expanding repertoire
of coactivators, including a novel RNA-based one re-
ported in this issue of Cell (Lanz et al., 1999), have been
recently isolated, and they are the focus of this brief
Figure 1. Functional Domains of Nuclear Receptors
review.
A/B and F domains vary in size and primary sequence among the
p160/HAT Coactivators superfamily. CoR refers to corepressor binding site present in some
A series of in vitro biochemical and yeast two-hybrid nuclear receptors. AF1 and AF2 refer to two distinct activation func-
tions (see text for details).studies in search of proteins interacting with nuclear
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receptors in the context of reporter-based transfection
assays, and the link to HAT function is provocative.
Nevertheless, their requirement in nuclear receptor
transactivation function has not yet been definitively
established. We still await direct demonstration of
p160's contribution to receptor function in a cell-free,
in vitro transcription assay. In contrast to other tran-
scription factors, p160 coactivators are not conserved in
lower species, including Drosophila and yeast, although
receptor homologs exist in insects and nuclear recep-
tors are capable of transactivating in yeast upon exoge-
nous expression. Moreover SRC-1's role in a physiologi-
cal context has been disappointing; null mice do not
exhibit dramatic phenotypes. Immunohistochemistry in-
dicates that ERa and SRC-1 do not colocalize in rat
mammary epithelium, although estrogen induction of
progesterone receptor (a known target gene of ER) oc-
curs in epithelium (Shim et al., 1999). These results may
point to a functional redundancy of p160 and related
coactivators. A challenge for the immediate future is the
clarification of their expected biological relevance and
overall impact on nuclear receptor signaling.
Complexity through an RNA Coactivator
A surprising deviation from the p160/CBP paradigm,
and perhaps from our traditional view of transactivation
in general, is the identification of an RNA coactivator
for steroid receptors, described by Lanz et al. (1999). A
two-hybrid screen for potential N-terminal human pro-
gesterone receptor (PR) AF1-interacting proteins led to
the isolation of several related cDNAs with a strongly
conserved core sequence but highly divergent 59 and 39Figure 2. Models of Nuclear Receptor±Coactivator Complex Inter-
regions. The isoforms all had potent coactivation activityactions
with steroid (type I), but not nuclear (type II) receptors,(A) p160 coactivators such as SRC-1 anchor a complex comprised
suggesting that the coactivator, termed SRA, works ex-of CBP/p300 and p/CAF to nuclear receptors through ligand-depen-
dent AF2 interactions and, in some cases, MAP kinase±inducible clusively through the N-terminal AF1 domain (which was
phosphorylation sites in the AF1. A ribonucleoprotein complex com- used as the original bait). Things took a strange but
prised in part of SRA RNA may serve to anchor SRC-1, and perhaps exciting turn when Lanz and colleagues realized that
other proteins, to the type 1 (steroid) receptor AF1, depicted here
their original GAL/SRA fusion used in the two-hybridas a DNA-bound homodimer. The net effect of these interactions
screen contained an in-frame stop codon that prema-would be to provide HAT activity, resulting in a remodeling of chro-
turely terminated translation of the fusion protein, andmatin.
(B) A distinct coactivator complex comprised of DRIP/TRAP and that attempts to in vitro translate SRA protein or detect
Mediator/SRB subunits is recruited to nuclear receptors in a ligand- it with an antipeptide antibody raised against SRA failed.
dependent manner through a single subunit, DRIP205 (TRAP220). Various mutants that lacked ATGs or changed reading-
Shown here is a DNA-bound nuclear receptor NR (red)/RXR (green) frames leading to mutiple stop codons all retained the
heterodimer. The DRIP/TRAP complex is depicted here as blue and
capacity to coactivate PR transcription in transfectionlight gray spheres; Mediator/SRB subunits that are shared between
assays. These results led the authors to a hypothesisDRIP/TRAP and RNA Pol II (light gray) suggests that coactivation
that SRA acts as an RNA, which was subsequently sup-of nuclear receptors by the DRIP/TRAP complex can occur, at least
in part, through recruitment or stabilization of RNA Pol II holoen- ported by the demonstration of cycloheximide-resistant
zyme. The two complexes in (A) and (B) might act independently, or coactivation of reporter mRNA expression, and the frac-
in a step-wise fashion, where p160/CBP coactivators act to remodel tionation of SRA RNA in a 600±700 kDa complex that
chromatin, thereby opening up promoter regions to the DRIP/TRAP coeluted and coimmunoprecipitated with SRC-1 (but
complex, which could then interact directly with Pol II.
not CBP/p300). The fact that SRA can be detected in a
large protein complex suggests that it might serve as
part of a ribonucleoprotein scaffold through which
prototypical yeast HAT, GCN5, is part of a 20 or so SRC-1 is recruited to steroid receptors. The evidence
subunit complex containing TAFs and TAF-like proteins for multisubunit complexes containing coactivator func-
(Ogryzko et al., 1998); it interacts with both CBP and tion is rapidly accumulating (see below); what is novel
some p160 coactivators, as well as directly with nuclear here is an RNA species anchoring such a complex. How-
receptors (Chen et al., 1997; Blanco et al., 1998). Thus, ever, if SRA indeed acts in concert with SRC-1, it is
one can imagine a growing HAT-containing, chromatin- puzzling that its effects are restricted to steroid recep-
remodeling complex comprised of CBP, p160, and tors, despite the fact that SRC-1 influences a much wider
p/CAF recruited to nuclear receptors in response to hor- spectrum of receptor family members.
mone-binding (Figure 2A). If, however, the ultimate role for SRA is structural,
should it be considered a true coactivator? A similarThe p160 family clearly confers coactivation to nuclear
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question could be posed for cyclin D1, which can appar- questions about selectivity. Phosphorylation can also
have an inhibitory effect: MAPK-induced phosphoryla-ently activate ER independently of estrogen by virtue
of its ability to bind both SRC-1 and ER, bridging the tion of N-terminal residues in PPAR-g reduces its ability
to transactivate (Hu et al., 1996), apparently by decreas-coactivator to the receptor (Zwijsen et al., 1998). And if
SRA RNA is a platform for SRC-1, then how did it come ing its LBD's intrinsic binding affinity for PPAR ligands
(Shao et al., 1998). Clearly the implications of receptorto us through a yeast two-hybrid screen, given that yeast
does not contain a SRC-1 homolog but PR is known to regulation by phosphorylation are manifold, but its bio-
logical role still needs to be more convincingly demon-be active in yeast? The authors suggest the contribution
of endogenous yeast proteins that can substitute for strated in a physiological context.
Contacts with RNA Polymerase II: The DRIP/TRAPSRC-1.
Many other questions arise from the unusual results Coactivator Complex
Although the sheer number of coactivators and the novelof Lanz. For example, can other RNA species substitute
for or coexist with SRA, and which RNA polymerase mechanisms by which they are recruited to receptors
might appear mind-numbing, a recently characterizedtranscribes SRA? Sensitivity to a-amanitin could directly
rule in or out a role for RNA polymerase II. Does SRA multisubunit complex that binds to vitamin D receptor
(VDR) (Rachez et al., 1998), thyroid hormone receptorunderscore a general role for RNA in transcriptional co-
activation? Is there any advantage to using RNA as a (TR) (Fondell et al., 1996), and, most likely, many other
members of the nuclear receptor family, points to theplatform for protein factors that function as coactiva-
tors? Finally, the novel findings of Lanz and colleagues ultimate generality of transactivation. This complex,
called DRIP or TRAP, is recruited to the LBD AF2 coredo not necessarily preclude a more active role for SRA,
where the RNA might actually possess intrinsic catalytic in response to ligand-binding through a single subunit
(DRIP205/TRAP220) via one LXXLL motif in much theactivity, or is capable of inducing productive allosteric
changes on its bound protein factors, such as SRC-1. same manner as the p160 coactivators. DRIP205 an-
chors the other 14±16 proteins comprising the DRIP/Ligand-Independent Recruitment of Coactivators
by Phosphorylation TRAP complex to the receptor, thereby conferring hor-
mone-dependent recruitment of what appears to be aOther signal transduction pathways impinge on nuclear
receptors independently of hormonal ligands. These ap- preformed complex. DRIP/TRAP is required for ligand-
dependent transcription activation in vitro, which nota-pear to involve the activation of several kinases, includ-
ing cyclin-dependent kinases, and MAP kinase (MAPK) bly has not yet been demonstrated for the p160 coacti-
vators. Several DRIP/TRAP subunits are homologous toby growth factors (reviewed in Garabedian et al., 1997
and references therein). In two papers in the April issue proteins described as components of Mediator (Gu et
al., 1999; Rachez et al., 1998), a complex that togetherof Molecular Cell, the groups of GigueÁ re and Ingraham
demonstrate that MAPK-induced phosphorylation of with SRB proteins associates with RNA polymerase II
(Pol II) through its large subunit's carboxy-terminal re-specific serines within the N-terminal AF1 of estrogen
receptor b (ERb) or the orphan receptor steroidogenic peat domain (CTD). This suggests that DRIP/TRAP, per-
haps through Mediator/SRB subunits, might function infactor 1 (SF-1), respectively, lead to an enhancement of
coactivator recruitment and subsequent transactivation. part by targeting Pol II holoenzyme to promoters (Figure
2B). The generality of this complex stems from the unex-For ERb, serine phosphorylation in AF1 (Ser-106 and
Ser-124) stimulates the recruitment of SRC-1 to the AF1 pected observation that other activators unrelated to
nuclear receptors, including Sp1, recruit the DRIP/TRAPdomain; this occurs independently of AF2 and regard-
less of the presence of the mixed agonist/antagonist complex or subcomplexes (called CRSP in Ryu et al.,
1999), and that several of the DRIP/TRAP subunits aretamoxifen (Tremblay et al., 1999). However, a ªpureº
antiestrogen did abolish phosphorylation-dependent present in two similar, if not identical, SRB-interacting
complexes, NAT and SMCC (Sun et al., 1998; Gu et al.,coactivator binding. As the authors point out, these re-
sults may have important clinical implications in the 1999). As studies on the DRIP/TRAP complex progress,
it is expected that their role in transcriptional regulationtreatment of breast cancer, since mixed agonist/antago-
nists such as tamoxifen and raloxifene would likely be will be further generalized; many classes of activators
are likely to recruit coactivator complexes and subcom-ineffective in ER-positive but estrogen-independent tu-
mors that are stimulated through a kinase-activated plexes containing the shared subunits of DRIP/TRAP
and SRB/Mediator. This additionally suggests that nu-pathway, whereas the use of pure antiestrogens might
be significantly more efficacious. clear receptors utilize a general mechanism for trans-
activation, but with inducibility imposed by ligand bind-Orphan nuclear receptors also appear to respond to
phosphorylation. SF-1 responds to MAPK-mediated ing, which is required for the recruitment of the DRIP/
TRAP complex.phosphorylation of a single serine residue (Ser-203)
within its AF1 domain by recruiting GRIP1, but it does How the DRIP/TRAP complex interfaces with the
p160/CBP/pCAF system, if at all, is perhaps one of theso through its putative LBD (Hammer et al., 1999). This
result and several others all point to an intramolecular key questions regarding nuclear receptor coactivation
presently. They may act independently or they may actcommunication between AF1 and AF2, whereby phos-
phorylation of the N-terminal AF1 might propagate con- in sequence, where the HAT coactivators remodel chro-
matin to then allow the DRIP/TRAP complex to recruitformational changes in the LBD presumably conducive
to coactivator recruitment. But the control of nuclear RNA polymerase II holoenzyme (Figure 2). In this model,
what influences the dissociation of the first complex andreceptor function by phosphorylation remains some-
what of an enigma. Multiple kinases and phosphoryla- the binding of the second is unknown. What is certain
is that as the number of coactivators and the complexestion sites on receptors appear to be involved, raising
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they form grow, the challenge of understanding their
underlying molecular functions will continue to generate
surprises and inspire insights into how gene transcrip-
tion is so exquisitely regulated.
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